z-logo
Premium
Development of fulminant Type 1 diabetes with thrombocytopenia after influenza vaccination: a case report
Author(s) -
Yasuda H.,
Nagata M.,
Moriyama H.,
Kobayashi H.,
Akisaki T.,
Ueda H.,
Hara K.,
Yokono K.
Publication year - 2012
Publication title -
diabetic medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.474
H-Index - 145
eISSN - 1464-5491
pISSN - 0742-3071
DOI - 10.1111/j.1464-5491.2011.03391.x
Subject(s) - medicine , fulminant , vaccination , diabetes mellitus , type 1 diabetes , type 2 diabetes , immunology , autoimmunity , seroconversion , endocrinology , antibody
Diabet. Med. 29, 88–89 (2012) Abstract Background  Fulminant Type 1 diabetes was originally reported as idiopathic Type 1 diabetes. Involvement of viral infections in the pathogenesis of fulminant T1D has been suggested, but the development of fulminant Type 1 diabetes after influenza vaccination has not been reported. Case Report  We report a case of fulminant Type 1 diabetes with thrombocytopenia following influenza vaccination. A 54‐year‐old man was admitted to hospital with hyperglycaemia and diabetic ketosis. Seven days before admission, he received a seasonal influenza vaccine for the prevention of influenza infection. On admission, blood glucose was 29 mmol/L and HbA1c 40 mmol/mol (5.9%). Fasting and 2‐h C‐peptide immunoreactivity were <0.0333 nmol/L and 0.0999 nmol/L, respectively. Anti‐GAD and anti‐IA‐2 antibodies were negative, so no autoimmunity seemed to participate in the etiology. ELISPOT assay also showed no association with T cell‐mediated autoimmunity. HLA genotypes were consistent with susceptibility to fulminant Type 1 diabetes. After the abrupt onset of diabetes, he showed mild thrombocytopenia, which has been observed for approximately 5 years after diabetes development. Conclusion  This is the first description of fulminant Type 1 diabetes after influenza vaccination. Our observation raises the possibility that influenza vaccination might trigger this condition via the TLR7 pathway.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here